Table 1.

Evaluation of antibodies to pVEGFR-2

VEGFR2 phosphoepitopeWestern blot analysis (HUVEC + VEGF-A ± AZD2171)Immunohistochemistry (Calu-6 xenografts)
pY951 RP (CST-2471)Positive (very weak)Negative
pY966 RP (CST-2474)Negative (cross-reactive)Stains tumor vessels
pY1054 RP (Biosource 44-1046)Positive (cross-reactive)Positive but variable (additional tumor cell staining)
pY1054/59 RP (Biosource 44-1047)Positive (cross-reactive)Positive but variable (additional tumor cell staining)
pY1175/1173 RP (Oncogene Res PC462)Positive (weak)Positive (specific for tumor vasculature)
pY1214/1212 RP (CalbiochemPS1012)Positive* (clean)Negative
pY1214/1212 RP (AZ 469)Positive (clean)Negative
pY1214/1212 RP (AZ CB1764)Positive (clean)Positive (specific for tumor vasculature)
  • NOTE: Positive indicates for Western blot; antibody specifically recognizes pVEGFR-2; for immunohistochemistry, antibody recognizes phosphoepitope in tumor vasculature. Negative indicates for Western blot; antibody does not recognize pVEGFR-2; for immunohistochemistry, antibody does not bind tumor vasculature.

    Abbreviations: RP, rabbit polyclonal; AZ, AstraZeneca.

  • * Batch specific.